Moneycontrol PRO
HomeNewsBusinessMarketsBrokerage Radar: Macquarie has 'Outperform' call on TCS, Bajaj Auto gets 'Underperform' rating from CLSA

Brokerage Radar: Macquarie has 'Outperform' call on TCS, Bajaj Auto gets 'Underperform' rating from CLSA

Check out the latest brokerage calls and analyst comments on the stocks in action today. Our coverage includes TCS, Bajaj Auto, Larsen & Toubro and more.

September 18, 2024 / 08:17 IST
Brokerage Radar

Brokerage Radar

Check out the latest brokerage calls and analyst comments on the stocks in action today. Our coverage includes TCS, Bajaj Auto, Larsen & Toubro and more.

Macquarie On TCS
Outperform Call, Target `5,740/Sh
Co Is Growing Faster Than Infosys In Spending Rebounds
Expect More Cloud Migration Deals To Be Bundled Between Applications & Infra Services
See TCS As Better Positioned Than Infosys
Expect TCS To Grow Faster Than Infosys In Both FY26 & FY27

CLSA On Bajaj Auto
Underperform Call, Target `7,000/Sh
With An Attractive Price Point Of `2.17 Lk, Believe Speed T4 Hits Right Spot
Bajaj Auto Delivered 60,000 Triumph Motorcycle In FY24
New Launch Looks Promising But Remain Cautious On Increasing Competitive Intensity
Cautious Over Growth Moderation In >250cc Motorcycle Segment
There Is Continued Pressure In Key Export Markets

Jefferies On L&T
Buy Call, Target `4,165/Sh
Co Reiterated FY25 Order Flow & Rev Growth Outlook Is Achievable Given The Pipeline & Orderbook
Rev Guidance Factors Execution Delays From Govt Activity Taking 3-6 Mths To Pick Up Post Elections
Believe Budget Gives Confidence On Medium-term Double-digit Capex Growth Being Intact

Jefferies On Adani Ports
Buy Call, Target `1,910/Sh
Management Is Confident On Double-digit Volume Growth
Co Retained Its FY25 Volume Guidance With New Port Operations Expected In H2
Capex Prudence And Return Focus Remain
Mkt Sh Gains Continue, With Dedicated Freight Corridor Commissioning At Mundra Also Helping

Citi On LTIMindtree
Sell Call, Target `5,635/Sh
Co Continues To Reiterate That Q2 Revenue Growth Trends Will Likely Be Similar To Q1
Margin May See Continued Pressure As Growth Is Moderate & From Cost Takeout Deals
Valuations At 32x FY26 Consensus EPS

Kotak Instl Eq On Emcure
Initiate Add, Target `1,655/Sh
Emcure Is One Of The Few Indian Pharma Majors With No Direct US Generics Exposure
There Is Greater Earnings Stability With No Direct US Generics Exposure
Co Has Built A Complex Portfolio Across India, Canada, Europe And EMs
Expect Emcure To Report A 14% Overall Sales CAGR Over FY2024-27
On A Low Base, Expect Improved Productivity Post The 20%+ Field Force Addition Since FY22
Higher Capacity Utilisation Of New Facilities To Drive Robust 19%/30% EBITDA/EPS CAGR Over FY24-27

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Moneycontrol News
first published: Sep 18, 2024 08:17 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347